Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Regeneron Pharmaceuticals, Inc
Enrolling: Male and Female Patients
IRB Number: AAAS2588
U.S. Govt. ID: NCT03761108
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study will look at the safety of a drug (REGN5458) in patients with multiple myeloma. It will also try to find out what the best dose of REGN5458 is and look for any signs that REGN5458 can help treat your cancer. REGN5458 is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) for any condition.
Investigator
Divaya Bhutani, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with Multiple Myeloma? Yes No
Has your disease progressed? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE